In patients with relapsed or refractory systemic lupus erythematosus, allogeneic CAR-NK cell therapy may offer a safe ...

From neutrophil extracellular traps to genetic networks that underlie the disease and new targeted therapies, important advances in 2011 improve our understanding of the pathogenesis of systemic lupus ...

Objective This study aimed to evaluate the prevalence and predictors of cardiovascular disease (CVD), chronic kidney disease ...

In systemic lupus erythematosus, chronic spontaneous urticaria did not raise SLEDAI scores, but cylindruria, mucosal ulcers, ...

Activation of certain memory B cells may be driving systemic lupus erythematosus incidence in individuals who had ...

During the Phase IIb study (NCT05688696), 187 patients with SLE were randomised to receive 48 weeks of treatment with either 75mg or 50mg orelabrutinib or placebo. Within the 48-week treatment window, ...

Critically ill patients with systemic lupus erythematosus show reduced ICU survival, driven largely by renal dysfunction, with glucocorticoids potentially mitigating mortality risk.

What is Systemic Lupus Erythematosus? Systemic Lupus Erythematosus (SLE) is a chronic disease with many manifestations. It is an autoimmune disease in which the body's immune system is directed ...

Objective To characterise the age-related impact of organ damage patterns on health-related quality of life (HRQoL) in ...

A recent review highlights melatonin's potential in diagnosing and treating systemic lupus erythematosus (SLE). Research indicates lower serum melatonin levels in SLE patients, suggesting diagnostic ...